SER: נכסים נקיים למניה בודדת Serina Pharma

Serina Therapeutics, Inc. (SER) relies on external contractors for synthesis and testing, maintaining control only over its patents. The book value per share metric, where GURU.Markets data informs this chart, confirms the capitalization, while the 0.74 indicator reflects current dynamics. Serina Therapeutics, Inc. (SER) is developing the POZ polymer system for neurology, accelerating the release of the SER-214 drug for Parkinson's disease therapy to minimize side effects.

For the biopharmaceutical sector, where Serina Therapeutics, Inc. (SER) is developing the POZ platform, the net asset value per ordinary share serves as an indicator of the business's tangible base net of all liabilities. This chart's price action helps determine whether accumulated capital covers R&D expenses, confirming the company's fundamental stability in the face of the high risks associated with creating precision medicines.